{
  "id": 16889468,
  "title": "Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences",
  "url": "https://urgent.news/2026/10/28/astellas-buys-option-on-preclinical-il-12-cancer-drug-from-audax",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-28T10:26:20.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/astellas-buys-option-to-preclinical-il-12-cancer-drug-from-audax-biosciences/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Astellas has taken an exclusive option to license a preclinical immuno-oncology asset from Australian biotech Audax Biosciences. The deal features $285 million that covers the upfront fee and a payment that becomes due if the ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}